66 results about "Cerebral cancer" patented technology

The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.

The invention discloses a traditional Chinese patent medicine with the components of plant polysaccharide and bamboo extract for treating medium and terminal cancer, which has a formula as follow: 10 kg of whangee, 5 kg of CV.Ventricousinternode, 10 kg of moso bamboo, 5 kg of palm bamboo, 5 kg of phyllostachys glauca, 10 kg of fishscale bamboo and 5 kg of fortune paulownia bark. A method for preparing the traditional Chinese patent medicine comprises the following steps: adding 50 kg of water into the total 50 kg of the medical materials; decocting the mixture to obtain 200 ml to 400ml of concentrated material; adding mineral trace elements: 0.01 milligrams of calcium, 0.01 milligrams of ferrum, 0.01 milligrams of zinc, 0.01 milligrams of selenium, 0.01 milligrams of iodine and 0.01 milligrams of potassium which are essential to the body into the concentrated material after removing impurities and filtering; finally, fermenting the final mixture to obtain the medicine, and bottling the medicine for use. The traditional Chinese patent medicine has the beneficial effects of treating medium and terminal esophagus cancer, gastric cancer, intestinal cancer, liver cancer, cerebral cancer and other cancers and treating gastritis, gastric ulcer, hepatitis, rhinitis and other inflammation. In addition, the traditional Chinese patent medicine can be also used for treating skin cancer and various kinds of skin diseases by exterior spreading. The traditional Chinese patent medicine takes effect rapidly and has no toxic and side effect.

The present invention provides a method of screening brain tumor patients for treatment with inhibitor of CSF-1R, based on differential gene expression including adrenomeduUin (ADM), arginase 1 (ARG1), clotting factor F13A1, mannose receptor C type 1 (MRC1 / CD206), and protease inhibitor SERPINB2 after treatment with the inhibitor. Based on the same differential gene expression profile, the present invention also provides a method of screening a compound to treat brain cancer.

The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of E1A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway.

The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.

Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.

Nanoparticle having a crosslinked chitosan-polyethylene oxide oligomer copolymer coating to which O6-benzylguanine is covalently coupled, compositions that include the nanoparticle, and methods for using the nanoparticle to treat brain cancers.

Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I):including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.

The invention discloses a Ras and HDAC dual inhibitor as well as a preparation method and an application thereof. The Ras and HDAC dual inhibitor has a structure of general formulas I and II and can be used for preparing a medicine for treating chronic inflammation and treating tumors of liver cancer, pancreatic cancer, lung cancer, breast cancer, cerebral cancer, colon cancer and stomach cancer.

The invention discloses a health-care konjac constipation relieving capsule and a preparation method thereof. The capsule is prepared from 85-95g of konjac gum, 5-10g of black rice, 0.5-2g of starch and 0.5-2g of senna leaves. The preparation method comprises the following steps of: material preparation, mixing and capsule preparation. The capsule and the preparation method have the following advantages: the capsule meets the requirement of human bodies for dietary fibers, can be used for overcoming the suffering from constipation, reducing the morbidity of constipation diseases, balancing pHvalues of intestines and stomachs, engendering liquid and allaying thirst, softening bulk feces, expelling toxins and promoting defecation, and effectively overcoming the suffering from constipation,is suitable for every one and does not have any toxic or side effect; the preparation method is simple and is low in production cost; and after being formed, the capsule product is convenient to eat,has a good effect and simultaneously has the effect of treating diabetes, piles, recta, colons, breasts, lymph and cerebral cancers in an aided manner.

The present invention relates to substances and compositions thereof useful in the control of cancer stem cell persistence and concomitant tumor recurrence and / or control of tumor growth. In particular, the invention relates to substances and compositions useful in the treatment of cancers and / or tumors linked to cancer stem cells, preferably brain cancers and / or tumors, in a subject.

The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence.

The invention discloses a cerebral cancer suppressing phycocyanin-polylactic acid-adriamycin micelle. Phycocyanin and PLA-PEG-PLA are utilized as raw materials, and a phycocyanin-polylactic acid no-load micelle is formed according to addition reaction of carboxyl and self-assembly principle based on hydrophilia and hydrophobicity. According to the self-assembly principle, adriamycin is coated in the no-load micelle to assemble by itself to form the micelle. The phycocyanin-polylactic acid-adriamycin micelle is a novel nano medicine capable of directly acting on tumor through blood-brain barrier to suppress cerebral cancer cells and capable of releasing slowly to retain in blood for a long time, thereby overcoming influence and limit of the blood-brain barrier to drug treatment effect. Besides, the micelle is prepared from natural or degradable components which are not involved with organic solvents during synthesis, has the advantages such as good biocompatibility, biodegradability, hypotoxicity, high loading capacity, and accordingly has high application potential in treating cerebral cancer.

The present invention provides a compound as represented by formula I, pharmaceutically acceptable salt, preparation method, use and pharmaceutical composition thereof. The compound represented by formula I is as follows:_(Formula I).The compound as represented by formula I has more excellent anti-cancer or anti-tumor effect, can inhibit various kinases inside cell and on cell surface simultaneously, and therefore has more efficient anti-cancer or anti-tumor effect, the kinases comprising PI3-K kinase and mTOR kinase. The pharmaceutical composition provided in the present invention can be used for treating cerebral cancer, glioblastoma, cervicocerebral cancer, lung cancer, melanoma, liver cancer, renal cancer, acute leukemia, chronic leukemia、non-small cell lung cancer、prostate cancer, thyroid cancer, skin cancer, colon cancer, rectal cancer, pancreatic cancer, ovarian cancer, breast cancer, myelodysplasia syndromes, esophageal cancer, sarcoma, osteosarcoma and rhabdomyoma.

The invention discloses a polyether type compound and application of a chelation form thereof, a hydration form thereof or pharmaceutically acceptable salt thereof in preparation of medicines. The medicines are used for treating at least one of brain cancer, skin cancer, kidney cancer, bone cancer, sarcoma, prostate cancer, uterine cancer, melanotic carcinoma, colorectal cancer, lymph cancer, leukemia, pancreatic cancer, breast cancer, liver cancer, lung cancer, stomach cancer and ovarian cancer. The medicines have relatively good effect of preventing and treating tumors.

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

The invention discloses an anti-tumor Chinese medicine extract, a preparation method and an application thereof; pulverized clematis terniflora is used or a clematis terniflora decoction piece is directly adopted, added with water or ethanol, heated, treated with reflux extraction for 2-5 times and then filtered; extract is merged, filtered or centrifugated, and then passes through macroporous resin; then water is firstly used for washing the resin, the water eluent is removed, then hydrous ethanol with the volume percentage of 30-95% is used for eluting, and the ethanol eluent is collected and concentrated into thick paste under reduced pressure, the thick paste undergoes decompressed concentration or spray drying so as to obtain the clematis terniflora extract which contains flavone and rutin no less than 20% and 0.1% respectively. The extract of the invention shows good in vitro inhibiting effect on the proliferation of leukemia Molt-4 cell strain, leukemia cell HL60, cerebral cancer U251 cell strain, esophagus cancer Eca-109 cell strain as well as liver cancer BEL-7402 cell strain. The anti-tumor Chinese medicine extract can be used for preparing the medicines for treating tumor, especially digestive system malignant tumor and the like diseases.

The invention relates to a Chinese traditional medicine composition for treating cancers. The Chinese traditional medicine composition is prepared from, by weight, 25-35 parts of ganoderma lucidum, 10-20 parts of ganoderma multiplicatum, 15-25 parts of lycopi herba, 5-15 parts of scutellariae barbatae herba, 5-15 parts of echinacea purpurea herb extractive, 3-7 parts of ginseng, 3-7 parts of curcumae rhizome and 3-7 parts of herba hedyotidis. The Chinese traditional medicine composition for treating the cancer is a broad spectrum anti-cancer medicine, is applied to liver cancer, stomach cancer, lung cancer, pancreatic cancer, rectal cancer, lymph cancer, parotid gland cancer, cerebral cancer, breast cancer, uterine cancer, ovarian cancer, bone cancer, liver embryo sarcoma, thyroid cancer and the like. By tonifying qi and consolidating body resistance, activating blood and removing blood stasis and relieving swelling and pain, the resistance of cancer patients to cancer cells is strengthened, treating both symptoms and root causes is achieved, synergistic anti-infection effects are exerted, the immunity is improved, the anti-cancer effect is increased, the further spreading of the cancer cells of cancer patients in the middle and advanced stage is effectively prevented, the curative effect is significant, and no toxic and side effects occur.

The present disclosure is directed to a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a TiPARP agonist, wherein the TiPARP agonist may be, for example, a tamoxifen compound (e.g., tamoxifen or derivative thereof), flavone or derivative thereof, isoflavone or derivative thereof, diindolylmethane compound, or chlorinated dibenzo-p-dioxin (CDBD) compound or derivative thereof. The cancer may be associated with elevated expression of HIF-1α and may be selected from, for example, breast cancer, colon cancer, lung cancer, skin cancer, brain cancer, blood cancer, cervical cancer, liver cancer, prostate carcinoma, pancreas carcinoma, gastric carcinoma, ovarian carcinoma, renal cell carcinoma, mesothelioma, and melanoma. The cancer may, in some embodiments, exclude breast cancer.

The present invention provides novel compounds of Formulae (I′) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK12), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.

The invention belongs to the field of medicines, and relates to fragrant sarcococca herb total alkaloids and a preparation method therefore, and application of fragrant sarcococca herb total alkaloids in preparation of antitumor drugs. The fragrant sarcococca herb total alkaloids are prepared by screening natural antitumor products, and then extracting and separating fragrant sarcococca herb total alkaloids from alkaloid parts of buxaceae sarocococca fragrant sarcococca herb through acid water, chloroform, ethyl acetate, acetone, ethanol, methanol and other organic solvents; the test shows that fragrant sarcococca herb total alkaloids have obvious activity on habiting various tumor cells, so that the fragrant sarcococca herb total alkaloids can be further used for preparing the antitumor drugs for treating stomach cancer, lung cancer, colorectal cancer, cerebral cancer and breast cancer, and however, the drugs are not limited to the effects above; in addition, the drugs can be applied to the whole body or part of the body through a carrier or an excipient.

The invention discloses a new use of Hedyotis hedyotidea (DC.) Merr. for treating hematopoietic malignancy leukemia, lymphoma, respiratory system neoplasm lung cancer, nasopharynx cancer, digestive system neoplasm esophagus cancer, gastric cancer, intestinal cancer, liver cancer, nervous system neoplasm cerebral cancer, urinary system neoplasm kidney cancer and reproductive system neoplasm ovarian cancer. By taking the Hedyotis hedyotidea (DC.) Merr. as a raw material and by combining pharmaceutic adjuvants, clinically applied medicines with various forms: decoctions, medicinal broth, injections, tablets, capsules and controlled-release pills, are prepared.

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

The invention discloses a preparation for treating cerebral cancer. The preparation is prepared from, by weight, 8-16 parts of radix scrophulariae, 10-14 parts of picris hieracioides, 7-12 parts of dried moss, 8-12 parts of pseudo-ginseng, 9-15 parts of glossogyne tenuifolia, 11-16 parts of winter jasmine, 8-13 parts of seeds of garden balsam, 6-15 parts of veronica linariifolia, 9-12 parts of rhizoma arisaematis, 8-14 parts of roots of perny holly, 6-13 parts of divaricate knotweed herb, 8-15 parts of seaweed, 6-9 parts of lumbricus, 9-13 parts of little groundcherry herb fruits, 7-14 parts of henry clematis roots, 8-11 parts of walnut branches and 10-15 parts of flowers of hyacinth dolichos. The preparation has the advantages that traditional drug properties are originally combined with traditional Chinese medicine modern pharmacology, sore healing and apocenosis, toxin expelling and cancer resistance, blood cooling and activating, qi promoting and hard lump eliminating, and wind expelling and refreshing serve as treatment rules, acceleration and proliferation of cancer cells are overcome, the cerebral cancer control rate is improved, the lifetime of a patient is prolonged, the medicine materials are low in cost, safe and free of side effects, and the popularization value is high.

Methods of treating a subject having a brain tumor comprising (a) administering an oncolytic virus and (b) administering a therapeutic antibody to said subject.

The present invention relates to a pharmaceutical composition for inhibiting growth of cancer stem cells, containing an aldehyde inhibitor and a biguanide-based compound. The pharmaceutical composition according to the present invention contains a combination of an aldehyde inhibitor and a biguanide-based compound, which can effectively inhibit the growth of cancer stem cells such as neurospheres and can also inhibit the proliferation, invasion and metastasis of cancer cells, thereby preventing and / or treating cancer such as brain cancer.